| abstract |
To date, there is no compound commercially available as a C17-20 lyase inhibitor, and a C17-20 lyase inhibitor that becomes a sex hormone biosynthesis inhibitor with a novel mechanism of action is craved from the clinical field. The following general formula (1) [Wherein R 1, R 2, R 3 and R 4 are each independently a hydrogen atom, a hydroxyl group, a halogen atom, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, phenoxy A group arbitrarily selected from the group consisting of a group, an acyl group, an acyloxy group, an optionally substituted amino group, a 5-membered heteroaromatic group, and an alkylenedioxy group formed by two adjacent groups Wherein R5, R6, R7, and R8 each independently represents a hydrogen atom or a lower alkyl group], or a pharmacologically acceptable salt thereof. C17-20 lyase inhibitors are provided. |